Krka sets up a dedicated biosimilars unit

Krka has set up an “independent organisational unit” dedicated to biosimilars as part of its stated intention to “embark on the area of similar biological medicines”. Noting that a separate unit had been set up “due to the scale and complexity of content in this field”, the Slovenian firm said it would place a “priority focus on treatments for autoimmune diseases and diabetes”.